quinidine has been researched along with acebutolol in 30 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (20.00) | 18.7374 |
| 1990's | 2 (6.67) | 18.2507 |
| 2000's | 14 (46.67) | 29.6817 |
| 2010's | 7 (23.33) | 24.3611 |
| 2020's | 1 (3.33) | 2.80 |
| Authors | Studies |
|---|---|
| Giacomini, KM; Schaner, ME; Zhang, L | 1 |
| Topliss, JG; Yoshida, F | 1 |
| Gao, F; Lombardo, F; Shalaeva, MY; Tupper, KA | 1 |
| Alvarez-Pedraglio, A; Colmenarejo, G; Lavandera, JL | 1 |
| Gao, F; Lombardo, F; Obach, RS; Shalaeva, MY | 2 |
| Thakker, DR; Troutman, MD | 1 |
| Caron, G; Ermondi, G; Lorenti, M | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Abraham, MH; Acree, WE; Ibrahim, A | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Alimuddin, M; Bulloch, D; Dahl, R; Grant, D; Lee, N; Peacock, M | 1 |
| Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Du-Cuny, L; Mash, EA; Meuillet, EJ; Moses, S; Powis, G; Song, Z; Zhang, S | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Campillo, NE; Guerra, A; Páez, JA | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
| Annand, R; Gozalbes, R; Jacewicz, M; Pineda-Lucena, A; Tsaioun, K | 1 |
| Bellman, K; Knegtel, RM; Settimo, L | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Abadi, AH; Abdel-Halim, M; Engel, M; Fathalla, RK; Hammam, MA; Hartmann, RW; Hefnawy, A; Keeton, AB; Maher, A; Maxuitenko, Y; Piazza, GA; Racheed, NAS; Sigler, S | 1 |
| Steyn, JM | 1 |
| Anderson, JL; Harrison, DC; Meffin, PJ; Winkle, RA | 1 |
| Chandraratna, PA | 1 |
| Koch, GG; Park, J; Shapiro, W | 1 |
| Müller, FO; Steyn, JM | 1 |
| Dreifus, LS; Morganroth, J | 1 |
| Arslan, M; Bingöl, H; Ciçek, S; Demirkilic, U; Kuralay, E; Ozal, E; Oztürk, OY; Tatar, H; Yilmaz, AT | 1 |
2 review(s) available for quinidine and acebutolol
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Antiarrhythmic agents and their use in therapy.
Topics: Acebutolol; Animals; Anti-Arrhythmia Agents; Digitalis Glycosides; Disopyramide; Humans; Lidocaine; Oxytocin; Phenytoin; Procainamide; Propranolol; Quinidine; Verapamil | 1980 |
3 trial(s) available for quinidine and acebutolol
| Article | Year |
|---|---|
Comparison of acebutolol with propranolol, quinidine, and placebo: results of three multicenter arrhythmia trials.
Topics: Acebutolol; Adult; Aged; Arrhythmias, Cardiac; Double-Blind Method; Female; Humans; Male; Middle Aged; Placebos; Propranolol; Quinidine; Random Allocation | 1985 |
Variability of spontaneous and exercise-induced ventricular arrhythmias in the absence and presence of treatment with acebutolol or quinidine.
Topics: Acebutolol; Adult; Aged; Arrhythmias, Cardiac; Cardiac Complexes, Premature; Circadian Rhythm; Clinical Trials as Topic; Delayed-Action Preparations; Double-Blind Method; Electrocardiography; Exercise Test; Heart Rate; Heart Ventricles; Humans; Male; Middle Aged; Monitoring, Physiologic; Quinidine; Random Allocation; Systole | 1982 |
Long-term prevention of atrial fibrillation after coronary artery surgery.
Topics: Acebutolol; Adult; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Coronary Vessels; Female; Fumarates; Humans; Male; Middle Aged; Postoperative Complications; Quinidine; Time Factors | 1997 |
25 other study(ies) available for quinidine and acebutolol
| Article | Year |
|---|---|
Functional characterization of an organic cation transporter (hOCT1) in a transiently transfected human cell line (HeLa).
Topics: Carrier Proteins; Corticosterone; HeLa Cells; Humans; Membrane Proteins; Midazolam; Organic Cation Transporter 1; Permeability; Recombinant Proteins; Structure-Activity Relationship; Tetraethylammonium Compounds; Transfection | 1998 |
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
ElogD(oct): a tool for lipophilicity determination in drug discovery. 2. Basic and neutral compounds.
Topics: 1-Octanol; Chromatography, High Pressure Liquid; Pharmaceutical Preparations; Solubility; Water | 2001 |
Cheminformatic models to predict binding affinities to human serum albumin.
Topics: Adrenergic beta-Antagonists; Antidepressive Agents, Tricyclic; Chromatography, Affinity; Cyclooxygenase Inhibitors; Databases, Factual; Humans; Hydrophobic and Hydrophilic Interactions; Penicillins; Pharmaceutical Preparations; Protein Binding; Quantitative Structure-Activity Relationship; Reproducibility of Results; Serum Albumin; Steroids | 2001 |
Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data.
Topics: Blood Proteins; Chemical Phenomena; Chemistry, Physical; Half-Life; Humans; Hydrogen-Ion Concentration; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Protein Binding | 2002 |
Novel experimental parameters to quantify the modulation of absorptive and secretory transport of compounds by P-glycoprotein in cell culture models of intestinal epithelium.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Blotting, Western; Cells, Cultured; Diffusion; Humans; Intestinal Absorption; Intestinal Mucosa; Models, Biological; Permeability; Pharmaceutical Preparations; Pharmacokinetics | 2003 |
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
Topics: Algorithms; Blood Proteins; Half-Life; Humans; Hydrogen-Ion Concentration; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Protein Binding; Statistics as Topic; Tissue Distribution | 2004 |
Contribution of ionization and lipophilicity to drug binding to albumin: a preliminary step toward biodistribution prediction.
Topics: Chromatography, Affinity; Hydrogen-Ion Concentration; Ions; Models, Molecular; Molecular Conformation; Pharmaceutical Preparations; Protein Binding; Quantitative Structure-Activity Relationship; Serum Albumin, Bovine; Ultracentrifugation | 2004 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Air to lung partition coefficients for volatile organic compounds and blood to lung partition coefficients for volatile organic compounds and drugs.
Topics: Air; Animals; Humans; Lung; Organic Chemicals; Probability; Rats; Tissue Distribution; Volatilization | 2008 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Determination of log D via automated microfluidic liquid-liquid extraction.
Topics: Automation; Biopharmaceutics; Microfluidic Analytical Techniques; Pharmacokinetics | 2008 |
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Computational modeling of novel inhibitors targeting the Akt pleckstrin homology domain.
Topics: Antineoplastic Agents; Blood Proteins; Caco-2 Cells; Cell Membrane Permeability; Computer Simulation; Drug Discovery; Drug Screening Assays, Antitumor; Humans; Models, Molecular; Phosphoproteins; Protein Binding; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-akt; Quantitative Structure-Activity Relationship | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Neural computational prediction of oral drug absorption based on CODES 2D descriptors.
Topics: Administration, Oral; Humans; Models, Chemical; Neural Networks, Computer; Permeability; Quantitative Structure-Activity Relationship; Technology, Pharmaceutical | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
QSAR-based permeability model for drug-like compounds.
Topics: Caco-2 Cells; Cell Membrane Permeability; Drug Discovery; Humans; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2011 |
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation | 2014 |
From Celecoxib to a Novel Class of Phosphodiesterase 5 Inhibitors: Trisubstituted Pyrazolines as Novel Phosphodiesterase 5 Inhibitors with Extremely High Potency and Phosphodiesterase Isozyme Selectivity.
Topics: Animals; Blood Proteins; Celecoxib; Cyclic Nucleotide Phosphodiesterases, Type 5; Drug Design; Female; Half-Life; Humans; Isoenzymes; Mice; Mice, Inbred C57BL; Microsomes, Liver; Phosphodiesterase 5 Inhibitors; Protein Binding; Pyrazoles; Recombinant Proteins; Stereoisomerism; Structure-Activity Relationship | 2021 |
A thin-layer chromatographic method for the determination of acebutolol and its major metabolite in serum.
Topics: Acebutolol; Chromatography, Thin Layer; Hydrogen-Ion Concentration; Quinidine; Solvents; Spectrometry, Fluorescence; Time Factors | 1976 |
Antiarrhythmic drugs: clinical pharmacology and therapeutic uses.
Topics: Acebutolol; Amiodarone; Anti-Arrhythmia Agents; Aprindine; Arrhythmias, Cardiac; Bretylium Compounds; Digitalis Glycosides; Disopyramide; Humans; Kinetics; Lidocaine; Mexiletine; Oxytocin; Phenytoin; Procainamide; Propranolol; Quinidine; Verapamil | 1978 |
Comparative effects of two commercially available blood collection tubes on plasma concentrations of drugs.
Topics: Acebutolol; Blood Specimen Collection; Carbamazepine; Diazepam; Digoxin; Ethosuximide; Humans; Nordazepam; Penbutolol; Pharmaceutical Preparations; Propranolol; Quinidine; Salicylates; Time Factors; Valproic Acid; Warfarin | 1980 |